Fig. 6.

MG-002 monotherapy prevents the development of spontaneous breast cancer lung metastasis. (A) Diagram outlining the experimental schedule to assess the ability of MG-002 to prevent the formation of spontaneous lung metastases from the primary tumor. (B) Using the experimental protocol outlined in panel A, mice were either treated by PO with MG-002 (0.5 mg/kg) or vehicle control every 3 d until surgical resection. The metastatic area in the lungs was quantified from H&E-stained sections (15 to 16 mice/group) and the average metastatic burden is shown ±SD. (C) Schematic diagram outlining the experimental schedule to assess the ability of MG-002 to treat lung metastases following lung colonization. (D) Using the protocol outlined in panel C, mice were either treated by PO with MG-002 (0.5 mg/kg) or vehicle control every 3 d until the experimental endpoint. The metastatic area in the lungs was quantified from H&E-stained sections (8 to 9 mice/group) and the average metastatic burden is presented ±SD. For panels B and D, representative H&E sections are shown (scale bar, 6 mm.) Statistical analysis was performed using a two-tailed (unpaired) Student’s t test. *P < 0.05.